Dr. David Farrell shares his poster and abstract at the American Heart Association meeting. COVID-19 patients can develop extremely high levels of gamma prime fibrinogen (GPF).
Gamma Diagnostics Inc. (GDx) and Oregon Health & Science University (OHSU) have signed a licensing agreement that seeks to further develop and commercially promote the use of Gamma Prime Fibrinogen (GPF) as an inflammatory and clotting risk biomarker.
Gamma Diagnostics has been awarded $277,710 USD by the National Institutes of Health to develop Antisense Oligonucleotides to Regulate Gamma Prime Fibrinogen Levels
25 years+ international experience in deal making, finance, value creation, business development, risk management and problem solving across diverse Industries.
The company says Gamma Prime Fibrinogen (GPF) assesses chronic inflammation and predicts death from heart attack and stroke. It also says GPF can diagnose cardiovascular and other inflammation-related conditions, including COVID-19, and predict disease severity.
Gamma Diagnostics describes GPF as a biomarker for predicting clotting and inflammation in cardiovascular disease and conditions such as COVID-19. It offers GammaCoeur kits to detect clotting and improve treatment options and outcomes.
